Casgevy, the world's first CRISPR-based medicine, costs $2.2 million per patient. By the end of 2024, just over 50 patients globally had begun treatment. There are roughly 100,000 Americans with sickle cell disease alone. Do the math on how long it takes to close that gap at current pace, and you will understand why the word "revolutionary" deserves to be used carefully.
That said, do not let the skeptics win here. CRISPR is not hype. It is a genuine scientific breakthrough that went from bacterial immune system curiosity to FDA-approved medicine in 11 years. That timeline is, by any historical standard, fast. The question worth asking is not whether CRISPR works. It does. The question is: works for whom, at what cost, and by when?
The Engineering Says: This Is Real Progress
Let's start with what the numbers actually look like. As of early 2025, more than 250 clinical trials employing gene-editing technologies are listed on public registries, with 136 CRISPR trials actively ongoing. That is not a research curiosity. That is a platform. Blood disorders still lead the field, but cardiovascular targets are accelerating fast.
The cardiovascular data is particularly interesting. Data shared from 14 participants in Verve Therapeutics' base-editing trial showed dose-dependent decreases in PCSK9 protein levels and LDL cholesterol; the three participants given the highest dose had an average of 59% reduction in LDL cholesterol. A one-time infusion. Permanent effect. If that holds through Phase 3, statins become a footnote.
Meanwhile, a Phase 1 Cleveland Clinic trial tested CTX310, a CRISPR therapy targeting the ANGPTL3 gene. Both LDL cholesterol and triglyceride levels were substantially reduced within two weeks after treatment and stayed at low levels for at least 60 days, with no serious adverse events related to treatment during short-term follow-up. Fifteen patients. Early data. But the signal is there and it is clean.
On the cancer side, a dose-escalation study involving 16 patients with blood cancers reported a 94% overall response rate, with 69% of patients displaying a complete response; seven of the 16 patients achieved complete response for over six months, with the longest running 24 months. Those numbers would be celebrated in any oncology trial. They should be celebrated here too.
CRISPR was adapted from bacteria for gene editing in human cells in 2012. Remarkably, only 11 years later it saw its very first approval as a medicine for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. If you think that pace is slow, compare it to the 30-year journey from HIV discovery to durable antiretroviral therapy.
The Part the Press Releases Skip
Now for the harder conversation. Because the gap between "this works in a trial" and "this reaches the people who need it" is where most medical technology stalls, and CRISPR has a version of this problem that is structural, not temporary.
The two gene therapy treatments for sickle cell disease recently approved by the FDA, Casgevy and Lyfgenia, cost $2.2 million and $3.1 million per patient, respectively. Between 50% and 60% of sickle cell patients are on Medicaid. That mismatch is not a billing problem. It is an access problem with real human consequences. The technology exists. The infrastructure to deploy it equitably does not.
The treatment itself is not a simple infusion. Right now, all of the ex vivo therapies require cells to be taken out of the body, edited and quality-controlled in a special lab, and then put back in the body after the patient undergoes intensive chemotherapy. Months of preparation. Highly specialized centers. Only certain hospitals are authorized to provide gene therapy for SCD; currently, there are close to 50 qualified treatment centers for Lyfgenia and over 35 authorized treatment centers for Casgevy in the United States. For a disease affecting 100,000 Americans, that treatment center count is not sufficient.
Then there is the safety question that does not get enough column inches. CRISPR-Cas systems can show off-target genotoxicity; even minimal off-target editing can lead to severe complications, representing a significant safety concern, and the clinical translation of many genome editing applications remains delayed. Beyond well-documented concerns of off-target mutagenesis, recent studies reveal a more pressing challenge: large structural variations, including chromosomal translocations and megabase-scale deletions; these undervalued genomic alterations raise substantial safety concerns for clinical translation. Next-generation tools like base editing and prime editing reduce this risk significantly, but they do not eliminate it. The field knows this. It is working on it. But anyone claiming current CRISPR therapies are fully understood at the genomic level is outrunning the data.
Substantial off-target genotoxicity concerns delay clinical translation of many CRISPR applications, and the absence of standardized guidelines leads to inconsistent practices across studies. That is not a reason to stop. It is a reason to be precise about what we know and what we do not.
Solvable, But Not the Way the Headlines Suggest
CRISPR is revolutionary in the same way that the first commercial jet was revolutionary: the engineering works, the physics is sound, and the early flights proved the concept. What came next was decades of iterating on safety, reducing cost, building infrastructure, and eventually making it accessible to people who are not wealthy or extraordinarily lucky. That process is not automatic. It requires deliberate policy and sustained investment.
In the United States, most people use private health insurance, which has a lesser incentive to cover very expensive treatments. That is the sentence that keeps CRISPR from being revolutionary in any practical sense right now. The science cleared every bar. The economics have not.
The optimists look at 136 active trials and see a revolution arriving. They are not wrong about the direction. The skeptics look at 50 patients treated worldwide and call it hype. They are not wrong about the scale. Both camps are describing the same data and reaching opposite conclusions based on what they choose to emphasize.
The engineering says: this technology is real, the safety profile is manageable and improving, and the clinical results in blood disorders and cardiovascular disease are legitimately exciting. It also says: a therapy that requires intensive chemotherapy prep, a specialized manufacturing facility, two months of hospital proximity, and a $2.2 million price tag is not yet a public health intervention. It is a medical breakthrough in the process of becoming one.
The distance between those two things is not measured in science. It is measured in reimbursement policy, treatment center capacity, manufacturing scale, and political will to fund access for the populations who actually carry these diseases. That part is solvable. It just will not solve itself.
